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Abstract
Background:  Flavanol-rich chocolate and lycopene-rich tomato extract have attracted interest as
potential alternative treatment options for hypertension, a known risk factor for cardiovascular morbidity
and mortality. Treatment of prehypertension (SBP 120–139/DBP 80–89 mmHg) may forestall progression
to hypertension. However, there has been only limited research into non-pharmacological treatment
options for prehypertension. We investigated the effect of dark chocolate or tomato extract on blood
pressure, and their acceptability as an ongoing treatment option in a prehypertensive population.
Methods: Our trial consisted of two phases: a randomised controlled three-group-parallel trial over 12
weeks (phase 1) followed by a crossover of the two active treatment arms over an additional 12-week
period (phase 2). Group 1 received a 50 g daily dose of dark chocolate with 70% cocoa containing 750 mg
polyphenols, group 2 were allocated one tomato extract capsule containing 15 mg lycopene per day, and
group 3 received one placebo capsule daily over 8 weeks followed by a 4-week washout period. In phase
2 the active treatment groups were crossed over to receive the alternative treatment. Median blood
pressure, weight, and abdominal circumference were measured 4-weekly, and other characteristics
including physical activity, general health, energy, mood, and acceptability of treatment were assessed by
questionnaire at 0, 8 and 20 weeks. We analysed changes over time using a linear mixed model, and one
time point differences using Kruskal-Wallis, Fisher's-Exact, or t-tests.
Results: Thirty-six prehypertensive healthy adult volunteers completed the 6-month trial. Blood pressure
changes over time within groups and between groups were not significant and independent of treatment.
Weight and other characteristics did not change significantly during the trial. However, a marked
difference in acceptability between the two treatment forms (chocolate or capsule) was revealed (p <
0.0001). Half of the participants allocated to the chocolate treatment found it hard to eat 50 g of dark
chocolate every day and 20% considered it an unacceptable long-term treatment option, whereas all
participants found it easy and acceptable to take a capsule each day for blood pressure.
Conclusion: Our study did not find a blood pressure lowering effect of dark chocolate or tomato extract
in a prehypertensive population. Practicability of chocolate as a long-term treatment option may be limited.
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Background
Prehypertension (systolic blood pressure (SBP) 120–139
mm Hg, diastolic blood pressure (DBP) 80–89 mm Hg) is
considered a precursor of hypertension and has been asso-
ciated with an increased risk of up to 3.5 times in cardio-
vascular morbidity and mortality later in life [1-6].
Treatment of prehypertension with an angiotensin-recep-
tor blocker for 2 years and follow-up at 4 years resulted in
a significant 27% reduction in new-onset hypertension in
the treated group compared to placebo [4].
Lifestyle modifications including dietary approaches have
been recommended for the management of prehyperten-
sion [1,7]. Because alternative and complementary treat-
ment options for blood pressure have become
increasingly popular [8,9], we investigated whether dark
chocolate or tomato extract would be effective or accepta-
ble treatment options for prehypertension.
Polyphenols, in particular flavanols, in chocolate have
been associated with the formation of endothelial nitric
oxide leading to vasodilation and lowering of blood pres-
sure [10-12], whereas the blood pressure lowering effect
of tomato extract has been linked to its high antioxidant
content, in particular the carotenoid lycopene, and its free
radical scavenging properties [13,14].
Chocolate has recently been a popular target in studies
investigating dietary effects on blood pressure [15-27].
However, most studies were either of short duration (2
weeks) [18-23,27] or had no control group without cocoa
[15] (same study reported also in [17]). In contrast,
tomato extract as the sole treatment for blood pressure has
been less widely researched [28], and only in a hyperten-
sive population. To date, a limited number of controlled
trials of longer than 2 weeks duration, in a prehyperten-
sive population, and exploring the effect of chocolate on
blood pressure have been conducted with conflicting
results [16,24]. Moreover, to our knowledge, no study to
date has compared the acceptability and practicability of
different treatment modalities for high blood pressure or
prehypertension.
Methods
Trial participants
The trial was conducted between June and December
2007 in Adelaide, South Australia. Recruitment started in
February 2007 by advertising in local newspapers, the
University websites, flyers around University notice-
boards, a public hospital's health promotion unit, and
items on local radio and evening television news pro-
grams. We received about 200 enquiries regarding the
study, with 87 individuals filling in a screening question-
naire assessing eligibility criteria including recent blood
pressure readings and availability for the 6-month study.
Inclusion criteria were: 1. Two of either four systolic or
diastolic blood pressure readings in the prehypertensive
range (SBP 120–139 or DBP 80–89 mm Hg), as measured
by our research nurse; 2. Not taking any antihypertensive
prescription medication. Exclusion criteria were: 1. Diabe-
tes mellitus; 2. Allergy to or intolerance of tomato or choc-
olate products. Forty-eight individuals did not meet
inclusion criteria (n = 31) or decided not to participate (n
= 17) including some who did not want to take the chance
of not being randomised to the chocolate group. The
remaining 39 healthy volunteers, aged between 22 and 73
years, provided written consent and were allocated to one
of three treatment arms (Figure 1).
The study was approved by the Human Research Ethics
Committee of The University of Adelaide.
Trial design
Our trial consisted of two phases: a three group parallel
randomised controlled trial (phase 1), followed by a
crossover of the two active treatment arms (phase 2). The
duration of each study arm was 12 weeks, consisting of an
8-week intervention period followed by a 4-week washout
period. Participants were randomly allocated to the choc-
olate (group 1), tomato extract (group 2), or placebo con-
trol (group 3) group by permuted block randomisation
using the SAS 9.1 software package [29]. Participants
remained in these three groups for 12 weeks (phase 1),
followed by the two active treatment groups (group 1 and
2) being crossed over to the other active treatment group
for an additional 12 weeks (phase 2). The control group
(group 3) ceased participation after phase 1 (at 12 weeks)
(Figure 1).
Over an 8-week period, group 1 participants were allo-
cated a 50 g daily dose (half of a 100 g block) of commer-
cially available dark chocolate with 70% cocoa,
containing 750 mg of polyphenols (Haighs Chocolates,
Adelaide, South Australia [30]); group 2 was allocated one
commercially available tomato extract capsule per day
containing 15 mg lycopene (Lyc-o-Mato® Tomato Lyco-
pene Complex capsules, LycoRed Ltd, Beer Sheva, Israel,
equivalent to four to five medium size tomatoes) [31];
and group 3 was allocated one placebo capsule per day
(matched to tomato extract capsules by colour, odour and
size, and containing mainly soy oil). Polyphenol content
of the trial chocolate was analysed by the Australian Gov-
ernment National Measurement Institute using the color-
imetric Folin-Ciocalteu assay. The trial chocolate
contained 15 mg/g of total polyphenols, equivalent to
395 umol/g ORAC (oxygen radical absorbance capacity).
To conceal allocation from investigators, trained staff not
involved in trial design and analysis handed out interven-
tion packs to participants. Blinding of participants toBMC Complementary and Alternative Medicine 2009, 9:22 http://www.biomedcentral.com/1472-6882/9/22
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Trial flow Figure 1
Trial flow.
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chocolate was impractical, however blinding of partici-
pants in the capsule groups was achieved by identical
packaging of active tomato extract and placebo capsules.
Blood pressure, weight and abdominal circumference
were measured every 4 weeks by a trained research nurse,
and questionnaires assessing physical activity, smoking
status, alcohol intake, general health, mood and energy
levels, habitual chocolate and tomato product intake, ease
and acceptability of treatment, were administered at base-
line and after each intervention period (at 0, 8 and 20
weeks). The questionnaire consisted of 5-point Likert-
scales, and closed and open ended questions, and can be
obtained from the corresponding author.
Habitual lycopene intake at baseline was estimated using
summary values of lycopene content in tomato products
based on five databases by Porrini M and Riso P [32]. Par-
ticipants were counselled to maintain their usual diet and
physical activity during the trial. Compliance and any
additional chocolate or tomato product intake was
assessed using participants' daily diary entries. A follow-
up questionnaire was administered 3 months after the
trial to assess chocolate and tomato consumption habits.
Blood pressure monitoring
Blood pressure was assessed by a trained research nurse
using a digital calibrated sphygmomanometer with
appropriately sized cuffs (Omron HEM-907, JA Davey Pty
Ltd). Participants rested for 5 minutes before four blood
pressure readings were taken in intervals of 3 minutes in
alternate upper arms in a seated position. Median SBP and
DBP at one time point were used for analysis to minimise
the effect of blood pressure variability.
Sample size and data analysis
On a population level a reduction of 4 to 5 mm Hg in SBP
and 2 to 3 mm Hg in DBP has been estimated to reduce
the risk of cardiovascular morbidity and mortality by up
to 20 per cent [33]. We calculated that a sample size of 60,
with 20 individuals in each group, would allow detection
of this difference at a power of 0.75 with 95% confidence
assuming a correlation of 0.5 among repeated measures.
As random number generation was based on a sample size
of 60, which we were unable to match in practice, num-
bers allocated to each of the three groups were slightly dis-
proportionate. Smaller group sizes between n = 10 and 15
in study 1 (three group parallel RCT) reduced the power
to 0.5 for detecting a difference of 4.5 mm SBP and 2.5
mm DBP, while reductions of 5–6 mm SBP and 3–4 mm
DBP would retain the power at 0.8. However, larger group
sizes in the crossover analysis (chocolate groups n = 26,
capsule groups n = 36) assessing acceptability of the two
treatment forms led to a reasonable effect size > 0.9.
Analyses were performed using SPSS version 15.0 and SAS
version 9.1 [29,34]. Between-group differences at one
time point were assessed by Kruskal-Wallis test (continu-
ous variables) and Fisher's-Exact test (binominal varia-
bles). A linear mixed model was used to assess within-
group and between-group differences of blood pressure
over time. Multiple comparisons were adjusted by Holm's
Stepdown Bonferroni procedure. P-values < 0.05 were
considered statistically significant. Blood pressure
changes over time were analysed separately for phase 1
(parallel three group RCT) and phase 2 (two group cross-
over). Adequate washout between studies was assumed.
Acceptability of two treatment forms (chocolate or cap-
sule) was analysed by student t-test.
Results
Baseline characteristics
We collected baseline characteristics of all 39 randomised
prehypertensive individuals. However, three participants
withdrew before the second time point for data collection
scheduled at week 4. All comparisons were subsequently
based on the thirty-six remaining participants. At baseline,
groups did not differ in anthropometric measures, habit-
ual chocolate or tomato product intake, physical activity,
alcohol intake, general health, energy and mood levels.
None of the participants smoked. A significantly higher
proportion of participants in the chocolate and tomato
extract groups took daily fish oil and/or garlic supple-
ments than in the control group (Table 1). As there is evi-
dence to suggest that fish oil or garlic supplementation
may have a blood pressure reducing effect in hypertensive
individuals [35,36], dietary supplementation was subse-
quently included as a binominal covariate in the analyses
of blood pressure. While median SBP and DBP at baseline
did not differ statistically between groups, observed differ-
ences were clinically relevant, and were therefore included
as covariates in the linear mixed model analyses of blood
pressure changes over time.
Withdrawals and compliance
As mentioned above three individuals withdrew after
baseline assessment but before the 4-week assessment. In
addition, one individual withdrew after crossover to study
2 (after 12 wks but before the 16 wk assessment). Two
individuals withdrew when allocated to a chocolate group
(one in phase 1, one in phase 2), both indicating that they
found the dark chocolate unpalatable (Figure 1). One
individual allocated to the tomato extract capsules
reported gastrointestinal upset and one individual allo-
cated to the control group withdrew due to illness appar-
ently unrelated to our trial. In total, 36 participants
completed phase 1, twenty-five completed phase 2, and
attended all monitoring sessions, respectively. Self-
reported diary entries indicated excellent compliance with
the study protocol and consumption of provided choco-BMC Complementary and Alternative Medicine 2009, 9:22 http://www.biomedcentral.com/1472-6882/9/22
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Table 1: Baseline characteristics
Mean (SD)
Characteristics Dark 
chocolate
Tomato 
extract
Control P-valuea
n = 11 n = 15 n = 10
Age, years 48.8 (12.2) 51.2 (12.1) 57.9 (13.4) .11
Weight, kg 80.3 (17.7) 74.0 (10.3) 75.9 (13.7) .63
Body mass index 26.9 (6.2) 26.2 (3.1) 26.2 (5.2) .87
Abdominal circumference, cm 85.7 (9.5) 87.5 (11.5) 82.2 (9.3) .65
Median systolic blood pressure, mm Hg 135.1 (12.5) 128.2 (11.4) 135.7 (12.4) .18
Median diastolic blood pressure, mm Hg 83.6 (10.5) 79.1 (7.5) 77.8 (8.6) .34
Self-reported...
Dark chocolate intake, g/wk 32.5 (55.0) 70.9 (166.9) 59.0 (61.3) .43
Milk chocolate intake, g/wk 60.0 (120.2) 73.7 (102.7) 99.0 (172.1) .42
Tomato product intake, d/wk 3.1 (1.7) 4.5 (1.4) 3.1 (1.9) .07
Estimated habitual lycopene intake (only subjects ≥ 105 mg/wk)c 211 (74), n = 2 194 (16), n = 2 210 (0), n = 1, not calculated
Moderate physical activity ≥ 30 min, d/wkd 2.9 (2.0) 3.8 (2.5) 3.3 (2.5) .65
Alcohol intake, times/wk 1.4 (1.7) 2.6 (2.3) 2.9 (2.8) .40
Standard drinks/wk 5.2 (6.6) 3.3 (3.0) 8.1 (11.1) .84
Smoking, cigs/d 0 0 0 1
5-point Likert scales
General healthe 2.3 (0.9) 2.0 (0.8) 2.2 (0.8) .58
Energy levelsf 2.5 (0.8) 2.3 (1.0) 2.3 (0.8) .65
Moodg 2.1 (0.5) 2.1 (0.7) 2.0 (0.7) .92
Bivariate variables
Gender
Male 7 7 5 0.7b
Female 4 8 5
Dietary supplement intake
If fish oil or garlic = yes 4 9 1 .04b*
no 7 6 9
a P-values are calculated by Kruskal-Wallis Test or b Fisher's-Exact Test
c Intake of one tomato extract capsule per day equals 105 mg lycopene per week.
d Moderate physical activity, e.g. brisk walk, cycling at regular pace, doubles tennis, swimming
e 5-point scale with 1 = excellent, 2 = very good, 3 = good, 4 = fair, 5 = poor
f 5-point scale with 1 = very energetic, 2 = moderately energetic, 3 = somewhat energetic, 4 = fatigued, 5 = very fatigued
g 5-point scale with 1 = very happy, 2 = happy, 3 = up and down, 4 = unhappy, 5 = very unhappy
* p < 0.05 indicates a significant difference between groupsB
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Table 2: Median BP ± SE (SD)
Median SBP ± SE (SD)
Phase 1 Phase 2
N Parallel RCT, 3 groups Crossover of two active groups
Group wk 0 wk 4 wk 8 washout wk 
12
P-value within group 
over time wk 0–12
Group wk 16 wk 20 Washout 
wk 24
P-value within 
group over 
time wk 0–24
Chocolate 11 135.0 ± 3.8 
(12.5)
136.9 ± 4.3 
(14.1)
133.1 ± 3.5 
(11.7)
128.6 ± 4.5 
(15.0)
.23 Tomato 131.0 ± 4.1 
(13.6)
131.2 ± 4.3 
(14.2)
127.6 ± 3.9 
(13.0)
.57
Tomato 15 128.2 ± 3.0 
(11.4)
130.9 ± 4.1 
(15.8)
125.7 ± 2.7 
(10.6)
129.3 ± 3.0 
(11.8)
.82 Chocolate 125.4 ± 2.9 
(10.9)
126.8 ± 2.8 
(10.3)
124.2 ± 2.2 
(8.1)
.79
Control 10 135.7 ± 3.9 
(12.4)
134.3 ± 4.8 
(15.2)
130.8 ± 5. 8 
(18.3)
134.0 ± 3.9 
(12.3)
.98
Median DBP ± SE (SD)
Chocolate 11 83.6 ± 3.2 
(10.6)
83.9 ± 4. 0 
(13.4)
84.5 ± 3. 5 
(11.6)
80.8 ± 3. 8 
(12.5)
.49 Tomato 82.8 ± 2.8 
(9.3)
82.6 ± 3. 4 
(11.3)
79.7 ± 3.7 
(12.3)
.91
Tomato 15 79.1 ± 1. 9 
(7.5)
79.0 ± 2.7 
(10.4)
77.5 ± 1.9 
(7.4)
79.2 ± 2.2 
(8.6)
.98 Chocolate 76.4 ± 2.1 
(7.7)
77.9 ± 2.2 
(8.2)
77.8 ± 1.7 
(6.2)
1.0
Control 10 77.8 ± 2.7 
(8.6)
76.6 ± 3.0 
(9.4)
77.3 ± 3.2 
(10.0)
77.3 ± 3.0 
(9.4)
.94
P-values were calculated using linear mixed model analysis. Between group differences over time (phases 1 and 2) were not significant (P-values not shown).BMC Complementary and Alternative Medicine 2009, 9:22 http://www.biomedcentral.com/1472-6882/9/22
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late or capsules. Additional chocolate or tomato product
consumption during the intervention and washout peri-
ods was negligible (data not shown).
Outcomes
Blood pressure
Observed blood pressure changes over time were incon-
sistent and independent of treatment (Figure 2). No sig-
nificant blood pressure changes over time within groups
or differences between groups were obtained (Table 2).
Median SBP values remained within the prehypertensive
range throughout the trial (120–139 mm Hg), while
median DBP values stayed within the prehypertensive and
upper normal range (75–89 mm Hg) (Table 2). There was
a trend towards median systolic blood pressure reduction
in the two active treatment groups over the 24 weeks of
the trial, but this trend was independent from the treat-
ment including the washout phases [p = 0.058; med SBP
reduction (SE) in group 1: -7.5 (5.3) mm Hg; in group 2:
-4.0 (4.7) mm Hg].
Other characteristics
Weight, body mass index (BMI), abdominal circumfer-
ence, physical activity, general health, energy and mood
levels were assessed at three time points at 0, 8 and 20
weeks (baseline, end of intervention period in phase 1,
and end of intervention period in phase 2). No significant
changes over time within the three groups were observed
(Table 3). Differences in characteristics between groups
remained insignificant (data not shown). Not all partici-
pants agreed to have their abdominal circumference
measured at all time points, therefore mean values are not
representative of all participants and changes over time
need to be interpreted cautiously.
Acceptability
At the end of the intervention periods of phases 1 and 2
we assessed acceptability and willingness to continue with
treatment long-term with daily consumption of chocolate
or a capsule. The two chocolate groups of phase 1 and
crossover phase 2 were analysed together, as well as all
capsule groups (tomato extract and placebo groups of
phase 1 and tomato extract group after crossover in phase
2). Differences in acceptability between the two treatment
forms were highly significant (p < 0.0001, effect size 0.9):
half of the participants allocated to the chocolate treat-
ment found it hard to eat 50 g of dark chocolate every day
and 20% considered it an unacceptable long-term treat-
ment option, whereas all participants found it easy and
acceptable to take a capsule each day for blood pressure
(Table 4). Unacceptable taste, concerns about fat content,
and side effects such as constipation and headache were
reported reasons for unacceptability of chocolate as a reg-
ular treatment option. The majority of participants stated
that they would be willing to continue treatment if it was
effective (Table 4). Follow-up of participants three
months after the trial revealed that tomato product con-
sumption did not change significantly, although 80% had
intended to add more tomatoes to their diet. However,
dark chocolate consumption increased after the trial in all
groups (Table 4).
Discussion
Our trial did not demonstrate an effect of either dark
chocolate or tomato extract on blood pressure in prehy-
pertensive individuals over 8 week intervention periods.
However, our trial provided clear insights into acceptabil-
ity and practicability regarding long-term treatment
modalities for blood pressure. While half of the partici-
pants expressed difficulty in daily consumption of 50 g
dark chocolate and 20% did not consider this a long-term
treatment option, all trial participants found it acceptable
to take a non-prescription capsule a day for their blood
pressure.
Dosages of active components in our trial treatment arms
were comparable to earlier controlled trials investigating
the effect on blood pressure of either dark chocolate
(~750 mg polyphenols daily) [15,16,18-23,26,27] or
tomato extract (15 mg lycopene daily equivalent to 4–5
medium size tomatoes) [28]. Previous studies of the use
of chocolate on blood pressure reported mixed results: a
meta-analysis by Taubert et al. [25] including 5 studies
found a significant blood pressure reducing effect of choc-
olate, however more recent publications include non-sig-
nificant findings in normotensive and prehypertensive
populations [15,16,22]. To date, only a few studies have
investigated the effect of tomato extract on blood pressure
[28,37]. While Engelhard et al. [28] demonstrated a signif-
icant effect of tomato extract in untreated hypertensive
individuals, this effect was not apparent in our prehyper-
tensive population using an identical dosage.
It is likely that blood pressure level at the start of treat-
ment (hypertension, prehypertension, normotension) is
associated with a treatment's effectiveness. Taubert et al.
[24] observed a trend towards a greater treatment effect of
smaller doses of chocolate in individuals with higher
starting blood pressures, and our recent subgroup meta-
analysis of the effect of garlic supplements on blood pres-
sure demonstrated that reductions in blood pressure were
clearly correlated with starting blood pressures [36].
Other factors, such as duration of intervention, frequency
of blood pressure assessments, and inclusion of washout
periods may also influence findings. While most trials
investigating the effect of chocolate on blood pressure
were of short duration (2 weeks, [15,16,18-23,26,27], a
few used longer intervention periods of 6 weeks [16], 8
weeks [15], or 18 weeks [24], and monitored blood pres-BMC Complementary and Alternative Medicine 2009, 9:22 http://www.biomedcentral.com/1472-6882/9/22
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Median systolic (A) and diastolic (B) blood pressure ± standard error (SE), during phase 1 (three group parallel RCT, 12 weeks)  and phase 2 (crossover of active treatment groups, 12 weeks) Figure 2
Median systolic (A) and diastolic (B) blood pressure ± standard error (SE), during phase 1 (three group parallel 
RCT, 12 weeks) and phase 2 (crossover of active treatment groups, 12 weeks).
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Table 3: Changes over time in selected characteristics of participants
Allocated group at 
baseline
Dark chocolate, n = 11 Tomato extract, n = 15 Control, n = 10
Mean (SD) Mean (SD) Mean (SD)
Time point, wks 0 8 20 P-valuea 0 8 20 P-valuea 0 8 P-valuea
Characteristics
Weight, kg 80.3 (17.7) 80.7 (17.9) 80.5 (18.5) 1.0 74.0 (10.3) 73.8 (10.3) 75.3 (9.0) .96 75.9 (13.7) 75.6 (13.6) .80
Body mass index 26.9 (6.2) 27.2 (6.9) 27.1 (7.2) .99 26.2 (3.1) 26.2 (2.7) 26.6 (2.7) .96 26.2 (5.2) 26.13 (5.1) .88
Abdominal circumference, cm 85.7 (9.5) 81.9 (10.0) 90.5 (13.0) (.43)b 87.5 (11.5) 87.0 (10.2) 89.8 (12.2) (.84)b 82.2 (9.3) 90.5 (13.0) (.22)b
n = 6 n = 7 n = 4 n = 13 n = 12 n = 8 n = 7 n = 6
Physical activity ≥ 30 min, d/wk 2.9 (2.0) 3.0 (1.8) 2.3 (0.9) .99 3.8 (2.5) 3.5 (2.2) 3.0 (2.0) .61 3.3 (2.5) 3.7 (2.6) .30
5-point Likert scales
General healthc 2.3 (0.9) 2.6 (1.1) 2.4 (0.7) .78 2.0 (0.8) 1.9 (1.1) 2.3 (1.0) .92 2.2 (0.8) 2.2 (0.8) .82
Energy levelsd 2.5 (0.8) 2.4 (1.2) 2.4 (1.3) .89 2.3 (1.0) 2.1 (0.9) 2.5 (1.2) .68 2.3 (0.8) 2.6 (1.2) .22
Moode 2.1 (0.5) 2.2 (0.8) 2.2 (0.6) .93 2.1 (0.7) 2. 0 (0.7) 2.1 (0.7) .86 2.0 (0.7) 2.3 (0.5) .20
Time points: Week 0 (baseline) and week 8 (end of intervention period of phase 1, parallel RCT); week 20 (end of intervention period of phase 2, crossover)
a P-values of differences over time within a group by linear mixed model analysis
b P-values not based on equal numbers at different time points
c 5-point scale with 1 = excellent, 2 = very good, 3 = good, 4 = fair, 5 = poor
d 5-point scale with 1 = very energetic, 2 = moderately energetic, 3 = somewhat energetic, 4 = fatigued, 5 = very fatigued
e 5-point scale with 1 = very happy, 2 = happy, 3 = up and down, 4 = unhappy, 5 = very unhappyBMC Complementary and Alternative Medicine 2009, 9:22 http://www.biomedcentral.com/1472-6882/9/22
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sure at multiple time points during the intervention peri-
ods [15,24]. Non-linear fluctuations in blood pressure
similar to those observed in our trial were seen over an 8-
week period by Allen RR et al. [15]. Furthermore, inclu-
sion of washout periods in our trial revealed a change of
blood pressure over time independent of treatment, sug-
gesting that blood pressure median values regressed
towards the mean over the 24 week (6 month) study
period. The majority of previous trials have not assessed
blood pressure changes during washout periods
[15,16,18,19,22,24,27].
Our trial had some limitations. First, the relatively small
sample size provided inadequate power to detect any dif-
ferences in blood pressure smaller than 5 mm Hg in SBP
or 3 mm Hg in DBP between the groups. These BP levels
are similar to estimated minimum BP reductions achieva-
ble with lifestyle modifications such as weight reduction
(to maintain normal BMI 18.5–24.5), consumption of a
diet rich in fruits and vegetables and low in saturated fat,
and engagement in daily moderate physical activity (≥30
min, e.g. brisk walking) [1]. However, it is possible that
smaller reductions in BP may have long-term cardiovascu-
lar health benefits. Second, inclusion of a control group
after crossover and follow-up over 24 weeks might have
assisted in interpretation of findings. Third, blinding of
participants to the chocolate treatment was impractical.
Lastly, although we assessed overall polyphenol content
of the trial chocolate, we were not in a position to assess
specific polyphenol components.
Table 4: Acceptability of treatment (chocolate or capsules)
Dark chocolate groups: Capsule groups: Mean (SD) P-valuea
70% cocoa, 50 g daily tomato extract (15 mg 
lycopene) or placebo, 1 
capsule daily
Ease of taking supple-
mentsb
50% found it hard to eat 50 g dark 
chocolate daily for 8 weeks
100% found it easy to take one 
capsule daily for 8 weeks
Chocolate groups: 2.4 (1.3)
Capsule groups: 1.3 (0.5) p < 0.0001
Acceptabilityc 20% found it unacceptable 100% acceptable Chocolate groups: 1.9 (1.0)
Capsule groups: 1.3 (0.5) p < 0.0001
Reason for unacceptability Unpalatable, too rich, encountered 
side-effects, such as constipation 
and headache
N/A
Withdrawals unpalatable (n = 2) gastrointestinal upset (n = 1); 
illness unrelated to study (n = 1)
Willingness to continue 
with treatment after triald
73% would continue with daily dark 
chocolate;
100% would continue with 
capsules;
Average dark chocolate 
consumption increased after the 
trial compared to baseline: mean 
increase = 44 ± 194 g/week
80% intended adding more 
tomatoes to diet;
35% would rather eat tomatoes 
than take a capsule
Willingness to pay for sup-
plementsd
73% would be willing to spend 
~A$1.25 for 50 g dark chocolate 
per day
66% would be willing to spend 
~A$1 per capsule per day
aP-values are calculated by student t-test,
b Ease was assessed using a 5-point Likert scale with 1 = very easy, 2 = easy, 3 = sometimes easy, sometimes hard, 4 = hard, 5 = very hard;
c Acceptability was assessed using a 4 = point Likert scale with 1 = very acceptable, 2 = acceptable, 3 = unacceptable, 4 = very unacceptable
dWillingness for long-term treatment was estimated by bivariate questions (yes/no)BMC Complementary and Alternative Medicine 2009, 9:22 http://www.biomedcentral.com/1472-6882/9/22
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It is debateable whether an initial run-in period should
have been included. While the majority of similar trials to
date on the effect of chocolate on blood pressure chose a
one-week cocoa/flavanol-free run-in period [16,19-
24,26], we instead assessed any habitual cocoa or tomato
product intake at baseline and throughout the study with
the aim to incorporate any individual changes in con-
sumption in the analysis. This study design provided
greater generalisability of findings to the whole prehyper-
tensive population seen in routine clinical practice.
Despite some limitations, our trial, for the first time, com-
pared the practicability of using two different treatment
modalities (chocolate or capsule) for people with blood
pressures in the prehypertensive range. Acceptability and
projected long-term compliance of chocolate as a treat-
ment option for blood pressure might be limited, suggest-
ing that chocolate may be a less practical treatment option
than capsules or pills. This finding was somewhat unex-
pected, as recruitment was mainly driven by the interest of
the public in a study using chocolate.
While our trial was not designed to assess the effect of
chocolate or tomato extract on other cardiovascular fac-
tors such as lipid levels or endothelial function, other
studies in prehypertensive and normotensive populations
have associated chocolate consumption with improved
coronary circulation [22], improved endothelial function
[10,27], induced nitric oxide dependent vasodilation
[11], or a reduction in serum total and LDL cholesterol (in
a population with elevated serum cholesterol) [15]. In
light of the potential cardiovascular benefits of chocolate
or tomato products on factors other than blood pressure,
and the potential to forestall progression to hypertension
by ongoing treatment (e.g. 2 years) of prehypertension
[4], future long-term studies assessing cardiovascular out-
comes, tolerance and compliance of a dietary treatment
would be of interest.
Conclusion
Our study did not find a blood pressure reducing effect of
50 g dark chocolate daily or 15 mg lycopene containing
tomato extract daily in a small prehypertensive popula-
tion over a period of 8 weeks. While we cannot rule out
cardiovascular health benefits of these dietary treatment
options, our study suggests that chocolate may not be an
acceptable long-term treatment option for some individu-
als.
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sure; BMI: body mass index; CI: confidence interval; d:
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number; RCT: randomised controlled trial; RR: relative
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SE: standard error; LDL: low density lipoprotein that
transports cholesterol and triglycerides; Wk: week.
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